The ESMO TAT 2026 event is being covered by various outlets, with discussions focusing on emerging trends and advancements in oncology. Reports highlight promising areas of research, including targeting the CD47-SIRPα axis, exploiting HER2 tumour heterogeneity, and the use of digital oncology and artificial intelligence in clinical trials. The event appears to feature presentations on early-phase trials, innovative approaches to immunotherapy, and potential solutions for addressing undruggable tumour targets.